Fundraising Fox
Tempothera
San Diego, US · Founded 2014 · Delaware corporation · 15 employees on LinkedIn · 1 known investors
Find your way into Tempothera
Sign up to find every way you can get introduced to Tempothera
- Your email: who you already know at Tempothera, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tempothera team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Tempo Therapeutics is a biotechnology company developing therapeutics, with a focus that includes dermatology. Its team works on a pipeline built around its underlying technology platform.
Founders & leadership
Tempothera was founded in 2014 by Westbrook Weaver and Donald Griffin.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.2M disclosed across 3 rounds · 2015–2026
▶$14MraisedSep 2026 · 43 investors · BiotechnologyRule 506(b)
- Westbrook WeaverExecutive Officer, Director
- Donald GriffinDirector
- Biren MehtaDirector
- Steven SandsDirector
- Eric RichmanExecutive Officer, Director
- Offering amount
- $14.5M
- Amount sold
- $14M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.3MraisedMar 2024 · 26 investors · BiotechnologyRule 506(b)
- Richard HancockDirector
- Donald GriffinDirector
- Steven RichieriDirector
- Robin SitverDirector
- Steven SandsDirector
- Biren MehtaDirector
- Westbrook WeaverExecutive Officer, Director
- Offering amount
- $16.8M
- Amount sold
- $16.3M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedAug 2021 · 39 investors · BiotechnologyRule 506(b)
- Westbrook WeaverExecutive Officer, Director, Promoter
- Steven RichieriExecutive Officer, Director
- Richard HancockDirector
- Dino Di CarloDirector
- Donald GriffinDirector
- Offering amount
- $3.9M
- Amount sold
- $3.8M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Tempothera.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase IISTTR | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.5M |
| National Science Foundation | Phase I | 2020 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Tempothera do?
- Tempo Therapeutics is a biotechnology company developing therapeutics, with a focus that includes dermatology. Its team works on a pipeline built around its underlying technology platform.
- Who founded Tempothera?
- Tempothera was founded by Westbrook Weaver, Donald Griffin in 2014.
- Who are Tempothera's investors?
- Tempothera's investors include Sugati Ventures.
- How much funding has Tempothera raised?
- Tempothera has disclosed $34.2M raised across 3 rounds.
- Where is Tempothera headquartered?
- Tempothera is headquartered in San Diego, US.